The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...

The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.

The FDA has approved Opdivo (nivolumab) as neoadjuvant and adjuvant treatment for adults with resectable NSCLC.

Pancreatic cancer is a stubborn and difficult cancer to treat. In fact, it has the highest death rate of all major cancers. Now, researchers have found a new treatment protocol may help some people ...

The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...

The Food and Drug Administration has approved Opdivo before and after surgery for some with non-small cell lung cancer.

In 2023, BMS received a similar approval across the pond. The National Institute for Health and Care Excellence (NICE) ...

Associations between age at diagnosis and chemotherapy dose reductions in women treated for stage I-IIIA breast cancer. Patients who received NACT and UBS and associated delays by sub-cohort (n = ...

Data suggest that neoadjuvant immune checkpoint inhibitor (ICI) therapy improves outcomes in patients with early-stage triple-negative breast cancer, but adjuvant ICI therapy does not.

Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults ...

Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...

The checkpoint inhibitor is now approved, based on CheckMate 77T findings, for neoadjuvant/adjuvant use in patients with ...